The Desmoid Tumor Research Foundation

January 2021

Oral Losartan After Limited Mandibulectomy for Treatment of Desmoid-Type Fibromatosis [Full Article]

Author Information

Curry DE(1), Al-Sayed AA(2), Trites J(2), Wheelock M(3), Acott PD(4), Midgen C(5), Johnson LB(2), Bezuhly M(3).

(1)Faculty of Medicine, Dalhousie University, Halifax, Nova Scotia, Canada. (2)Div of Otolaryngology-Head and Neck Surgery, Dept of Surgery, Dalhousie University, Halifax, Nova Scotia, Canada. (3)Div of Plastic Surgery, Dept of Surgery, Dalhousie University, Halifax, Nova Scotia, Canada. (4)Div of Nephrology, Dept of Pediatrics, IWK Health Centre, Halifax, Nova Scotia, Canada. (5)Dept of Pathology, IWK Health Centre, Halifax, Nova Scotia, Canada.

Publication

Ear Nose Throat J

Summary

We describe the case of a 3-year-old boy who presented with an enlarging, asymptomatic mass involving the left mandible. Biopsy revealed an immunohistochemical profile consistent with desmoid-type fibromatosis (DF). Despite the high likelihood of recurrence, conservative, mandible-sparing en bloc resection and limited mandibulectomy were performed. Pathological and immunohistochemical analysis of the resection specimen revealed DF with grossly positive margins and elevated expression of angiotensin II type 1 receptor. Postoperative medical treatment with the angiotensin receptor blocker losartan was initiated. The patient remains medically stable and disease progression-free on repeat imaging at 20 months post-resection. We describe for the first time the successful use of the angiotensin blocker losartan following conservative surgery for management of DF.

View Abstract